Back to the future: Antibody-based strategies for the treatment of infectious diseases
dc.contributor.author | Akdiş, Cezmi | |
dc.contributor.buuauthor | Oral, Haluk Barbaros | |
dc.contributor.buuauthor | Özakın, C. | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/İmmunoloji Anabilim Dalı/Mikrobiyoloji Bölümü. | tr_TR |
dc.contributor.scopusid | 7004498001 | tr_TR |
dc.contributor.scopusid | 57200678942 | tr_TR |
dc.date.accessioned | 2021-11-30T10:35:41Z | |
dc.date.available | 2021-11-30T10:35:41Z | |
dc.date.issued | 2002-07 | |
dc.description.abstract | Before antibiotics, sera from immune animals and humans were used to treat a variety of infectious diseases, often with successful results. After the discovery of antimicrobial agents, serum therapy for bacterial infections was rapidly forsaken. In the last two decades, problems with treatment of newly emerged, re-emerged, or persistent infectious diseases necessitated researchers to develop new and/or improved antibody-based therapeutic approaches. This article reviews some information on the use of antibodies for the treatment of infectious diseases, with special reference to the most seminal discoveries and current advances as well as available treatment approaches in this field. | tr_TR |
dc.identifier.citation | Oral, H. B. vd. (2002). "Back to the future: Antibody-based strategies for the treatment of infectious diseases". Molecular Biotechnology, 21(3), 225-236. | tr_TR |
dc.identifier.endpage | 239 | tr_TR |
dc.identifier.issn | 1073-6085 | |
dc.identifier.issue | 3 | tr_TR |
dc.identifier.pubmed | 12102547 | tr_TR |
dc.identifier.scopus | 2-s2.0-0036634582 | tr_TR |
dc.identifier.startpage | 225 | tr_TR |
dc.identifier.uri | https://doi.org/10.1385/MB:21:3:225 | |
dc.identifier.uri | https://link.springer.com/article/10.1385%2FMB%3A21%3A3%3A225 | |
dc.identifier.uri | http://hdl.handle.net/11452/22886 | |
dc.identifier.volume | 21 | tr_TR |
dc.identifier.wos | 000176468500004 | tr_TR |
dc.indexed.pubmed | Pubmed | tr_TR |
dc.indexed.scopus | Scopus | tr_TR |
dc.indexed.wos | SCIE | tr_TR |
dc.language.iso | en | tr_TR |
dc.publisher | Humana Press | tr_TR |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.relation.journal | Molecular Biotechnology | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | tr_TR |
dc.subject | Immunoglobulin | tr_TR |
dc.subject | Septic shock | tr_TR |
dc.subject | Antibody therapy | tr_TR |
dc.subject | Infectious diseases | tr_TR |
dc.subject | Human-immunodeficiency-virus | tr_TR |
dc.subject | Tumor-necrosis-factor | tr_TR |
dc.subject | Human monoclonal-antibody | tr_TR |
dc.subject | Placebo-controlled trial | tr_TR |
dc.subject | Intravenous immunoglobulin therapy | tr_TR |
dc.subject | Bone-marrow transplantation | tr_TR |
dc.subject | Gram-negative bacteremia | tr_TR |
dc.subject | B immune globulin | tr_TR |
dc.subject | Lipid-a domain | tr_TR |
dc.subject | Biochemistry & molecular biology | tr_TR |
dc.subject | Biotechnology & applied microbiology | tr_TR |
dc.subject | Animalia | tr_TR |
dc.subject | Bacteria (microorganisms) | tr_TR |
dc.subject | Cytomegalovirus | tr_TR |
dc.subject.emtree | Hepatitis B vaccine | tr_TR |
dc.subject.emtree | Bacterium antibody | tr_TR |
dc.subject.emtree | Monoclonal antibody | tr_TR |
dc.subject.emtree | Virus antibody | tr_TR |
dc.subject.emtree | Antibody | tr_TR |
dc.subject.emtree | Centoxin | tr_TR |
dc.subject.emtree | Chickenpox vaccine | tr_TR |
dc.subject.emtree | Cytomegalovirus vaccine | tr_TR |
dc.subject.emtree | Diphtheria antibody | tr_TR |
dc.subject.emtree | Hepatitis A vaccine | tr_TR |
dc.subject.emtree | Immunoglobulin | tr_TR |
dc.subject.emtree | Thromboembolism | tr_TR |
dc.subject.emtree | Interleukin 6 antibody | tr_TR |
dc.subject.emtree | Drug cost | tr_TR |
dc.subject.emtree | Measles vaccine | tr_TR |
dc.subject.emtree | Immunotherapy | tr_TR |
dc.subject.emtree | Mumps Vaccine | tr_TR |
dc.subject.emtree | Neutralizing antibody | tr_TR |
dc.subject.emtree | Bacterial infection | tr_TR |
dc.subject.emtree | Rabies vaccine | tr_TR |
dc.subject.emtree | Aseptic meningitis | tr_TR |
dc.subject.emtree | Rubella vaccine | tr_TR |
dc.subject.emtree | Antimicrobial activity | tr_TR |
dc.subject.emtree | Tetanus antibody | tr_TR |
dc.subject.emtree | Antigen binding | tr_TR |
dc.subject.emtree | Tumor necrosis factor antibody animal | tr_TR |
dc.subject.emtree | Bacterial infection | tr_TR |
dc.subject.emtree | Revie antibody production | tr_TR |
dc.subject.emtree | Human | tr_TR |
dc.subject.emtree | Drug research | tr_TR |
dc.subject.emtree | Immunotherapy | tr_TR |
dc.subject.emtree | Infection | tr_TR |
dc.subject.emtree | Drug use | tr_TR |
dc.subject.emtree | Infection | tr_TR |
dc.subject.emtree | Kidney failure | tr_TR |
dc.subject.emtree | Nonhuman | tr_TR |
dc.subject.mesh | Animals | tr_TR |
dc.subject.mesh | Antibodies, bacterial | tr_TR |
dc.subject.mesh | Antibodies, monoclonal | tr_TR |
dc.subject.mesh | Virus diseases | tr_TR |
dc.subject.mesh | Antibodies, viral | tr_TR |
dc.subject.mesh | Infection | tr_TR |
dc.subject.mesh | Bacterial infections | tr_TR |
dc.subject.mesh | Immunotherapy | tr_TR |
dc.subject.mesh | Humans | tr_TR |
dc.subject.mesh | Animal | tr_TR |
dc.subject.mesh | Bacterial infections | tr_TR |
dc.subject.mesh | Human | tr_TR |
dc.subject.mesh | Immunotherapy | tr_TR |
dc.subject.mesh | Virus diseases | tr_TR |
dc.subject.scopus | Respiratory Distress Syndrome, Adult; Allied Health Personnel; Disaster Disaster | tr_TR |
dc.subject.wos | Biochemistry & molecular biology | tr_TR |
dc.subject.wos | Biotechnology & applied microbiology | tr_TR |
dc.title | Back to the future: Antibody-based strategies for the treatment of infectious diseases | tr_TR |
dc.type | Review | |
dc.wos.quartile | Q3 (Biotechnology & applied microbiology) | tr_TR |
dc.wos.quartile | Q4 (Biochemistry & molecular biology) | tr_TR |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: